Identity
HGNC
LOCATION
11p11.12
LOCUSID
ALIAS
FGCP,FOLH,GCP2,GCPII,NAALAD1,NAALAdase,PSM,PSMA,mGCP
Non-annotated gene. Preliminary data : if you are an author who wish to write a full paper/card on this gene, contribute in submission tool
Other Information
Locus ID:
NCBI: 2346
MIM: 600934
HGNC: 3788
Ensembl: ENSG00000086205
Variants:
dbSNP: 2346
ClinVar: 2346
TCGA: ENSG00000086205
COSMIC: FOLH1
RNA/Proteins
Expression (GTEx)
Pathways
Protein levels (Protein atlas)
PharmGKB
| Entity ID | Name | Type | Evidence | Association | PK | PD | PMIDs |
|---|---|---|---|---|---|---|---|
| PA446155 | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Disease | ClinicalAnnotation | associated | PD | 22838948 | |
| PA450379 | mercaptopurine | Chemical | ClinicalAnnotation | associated | PD | 22838948 | |
| PA450428 | methotrexate | Chemical | ClinicalAnnotation | associated | PD | 22838948 |
References
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 38151791 | 2024 | Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma. | 0 |
| 38664014 | 2024 | Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas. | 1 |
| 38151791 | 2024 | Prostate-specific membrane antigen (PSMA) glycoforms in prostate cancer patients seminal plasma. | 0 |
| 38664014 | 2024 | Frequent Amplification and Overexpression of PSMA in Basallike Breast Cancer from Analysis of The Cancer Genome Atlas. | 1 |
| 36637862 | 2023 | Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy. | 2 |
| 36708571 | 2023 | Diagnostic Efficacy of PSMA and PSCA mRNAs Combined to PSA in Prostate Cancer Patients. | 2 |
| 37147881 | 2023 | PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. | 2 |
| 37247303 | 2023 | Prostate-Specific Membrane Antigen (PSMA) Expression in The Neovasculature of High Grade Gliomas (Histopathological and Immunohistochemical Study). | 1 |
| 36637862 | 2023 | Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy. | 2 |
| 36708571 | 2023 | Diagnostic Efficacy of PSMA and PSCA mRNAs Combined to PSA in Prostate Cancer Patients. | 2 |
| 37147881 | 2023 | PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy. | 2 |
| 37247303 | 2023 | Prostate-Specific Membrane Antigen (PSMA) Expression in The Neovasculature of High Grade Gliomas (Histopathological and Immunohistochemical Study). | 1 |
| 34974814 | 2022 | Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes. | 5 |
| 35162969 | 2022 | Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells. | 7 |
| 35378003 | 2022 | STAT3, VEGF, and PSMA Expression Patterns in Malignant Peripheral Nerve Sheath Tumors, Malignant Melanomas, and Glioblastomas: Does Staining Percentage and Intensity Have an Effect on Survival? | 1 |
Citation
Dessen P
FOLH1 (folate hydrolase 1)
Atlas Genet Cytogenet Oncol Haematol. 2003-02-01
Online version: http://atlasgeneticsoncology.org/gene/40619/folh1-(folate-hydrolase-1)
